Literature DB >> 25894144

Liver and kidney transplant in primary hyperoxaluria: a single center experience.

Gökhan Moray1, Tugan Tezcaner, Figen Özçay, Esra Baskın, Aydıncan Akdur, Mahir Kırnap, Sedat Yıldırım, Gülnaz Arslan, Mehmet Haberal.   

Abstract

OBJECTIVES: Primary hyperoxaluria, especially type 1, is a severe disease with multisystem morbidity and high mortality. We present 3 primary hyperoxaluria type 1 patients who underwent liver transplant, including living-donor liver transplant or combined liver and kidney transplant in our institution. CASE REPORTS: Patients who underwent liver transplant or combined liver/kidney transplant at our institution were evaluated, retrospectively. Between January 2002 and 2013, there were 3 patients who underwent transplant for primary hyperoxaluria. All 3 patients had disease onset in childhood, and the definitive diagnosis was established at age < 1, 6, and 8 years. Although early diagnosis was made, primary hyperoxaluria resulted in end-stage renal disease in 2 patients, and hemodialysis was introduced before liver transplant. All 3 patients underwent living-donor liver transplant. Case 1 was a 10-year-old girl who had an uneventful course after living-donor liver transplant, and she received a living-donor kidney transplant from the same donor 4 months after living-donor liver transplant. Case 2 was a 7-yearold boy who was the younger brother of the first patient; he did not have end-stage renal disease or any renal disorder after successful living-donor liver transplant. Case 3 was a 3-year-old boy who was diagnosed at age 2 months with renal disorders; although he was discharged from the hospital after living-donor liver transplant, he was readmitted because of unconsciousness that developed 1 day after discharge, and he died because of intracranial hemorrhage 2 months after liver transplant, unable to receive a kidney transplant.
CONCLUSIONS: Primary hyperoxaluria is a rare disorder that is difficult to diagnose until end-organ damage is severe. Outcomes may be improved with early and accurate diagnosis, aggressive supportive treatment, and correction of the enzyme defect by liver transplant before systemic oxalosis develops. However, kidney transplant or combined liver and kidney transplant is required in many primary hyperoxaluria type 1 patients because of the delayed diagnosis or long organ waiting time.

Entities:  

Mesh:

Year:  2015        PMID: 25894144

Source DB:  PubMed          Journal:  Exp Clin Transplant        ISSN: 1304-0855            Impact factor:   0.945


  4 in total

1.  Extreme living donation: A single center simultaneous and sequential living liver-kidney donor experience with long-term outcomes under literature review.

Authors:  Yücel Yankol; Cihan Karataş; Turan Kanmaz; Burak Koçak; Münci Kalayoğlu; Koray Acarlı
Journal:  Turk J Surg       Date:  2021-09-28

2.  Primary hyperoxaluria diagnosed after kidney transplantation failure: lesson from 3 case reports and literature review.

Authors:  Ruiming Cai; Minzhuang Lin; Zhiyong Chen; Yongtong Lai; Xianen Huang; Guozhi Zhao; Xuekun Guo; Zhongtang Xiong; Juan Chen; Hui Chen; Qingping Jiang; Shaoyan Liu; Yuexin Yang; Weixiang Liang; Minhui Zou; Tao Liu; Wenfang Chen; Hongzhou Liu; Juan Peng
Journal:  BMC Nephrol       Date:  2019-06-18       Impact factor: 2.388

3.  Clinical outcomes and temporal trends of immunological and non-immunological rare diseases in adult kidney transplant.

Authors:  Ester Gallo; Silvia Mingozzi; Alberto Mella; Fabrizio Fop; Roberto Presta; Manuel Burdese; Elena Boaglio; Maria Cristina Torazza; Roberta Giraudi; Gianluca Leonardi; Antonio Lavacca; Paolo Gontero; Omidreza Sedigh; Andrea Bosio; Aldo Verri; Caterina Dolla; Luigi Biancone
Journal:  BMC Nephrol       Date:  2021-11-17       Impact factor: 2.388

4.  Recurrent primary hyperoxaluria type 2 leads to early post-transplant renal function loss: A case report.

Authors:  Si Liu; Baoshan Gao; Gang Wang; Weigang Wang; Xin Lian; Shan Wu; Jinyu Yu; Yaowen Fu; Honglan Zhou
Journal:  Exp Ther Med       Date:  2018-02-07       Impact factor: 2.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.